HealthCare Global Enterprises Ltd - 539787 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate of HealthCare Global Enterprises Limited.24-03-2023
24-03-2023
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be meeting Investors/Analysts (Participants) as per the details below. Date Type of Interaction Participants March 21, 2023 Virtual Group Meetings Investors/Analysts20-03-2023
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings22-02-2023
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Earnings Call held with Analysts/Investors on February 09, 2023.16-02-2023
Buy HealthCare Global Enterprises; target of Rs 375: Prabhudas Lilladher
Prabhudas Lilladher is bullish on HealthCare Global Enterprises has recommended buy rating on the stock with a target price of Rs 375 in its research report dated February 11, 2023.15-02-2023
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement of Unaudited Financial Results of HealthCare Global Enterprises Limited ('the Company') for the quarter and nine months ended December 31, 2022.11-02-2023
Cancer care hospital chain HCG posts net profit of 42 crore in Q3
Currently, the cancer care hospital chain operates 22 cancer centres across India and Africa11-02-2023
Q3FY23 Quarterly Result Announced for Healthcare Global Enterprises Ltd.
Healthcare Global Enterprises announced Q3FY23 results: Q3FY23 & 9MFY23: Revenue Rs 4,247 million is up by +19% for Q3FY23 YoY. Adjusted EBITDA Rs 812 million is up by +28% for Q3FY23 YoY. Profit after Tax Rs 75 million turns positive for Q3FY23 YoY. Revenue Rs 12,527 million is up by +21% for 9MFY23 YoY. Adjusted EBITDA Rs 2,378 million is up by +35% for 9MFY23 YoY. Profit after Tax Rs 209 million turns positive for 9MFY23 YoY. Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, of HealthCare Global Enterprises Ltd. said, “At HCG, we strive to provide the best-in-class treatments for our patients across the value chain. We have been focusing on consistently upgrading our skill set with deep domain knowledge, upgradation of technology & urge to treat cancer for the best possible outcomes for every single patient under the HCG horizon. Technology and innovation play a pivotal role in enhancing healthcare systems, increasing access to healthcare services, and reducing the costs of therapies and consultations. It is the intelligent deployment of technology that serves the larger cause of healthcare. At HCG, patient care is approached holistically based on risk and severity of disease - from pre-admission to post-discharge – and is aimed at enhancing outcomes, lowering costs, and bettering resource management. Whether Linac technology, Teleradiology, Bioinformatics, Genomics, Robotic surgery, Digital pathology, or Adaptive AI, HCG's technology adoption is unflinchingly focused on patient outcomes. Our focus has been on Oncology in conjunction with local partners, has helped us built a strong legacy as a World-class Oncology Treatment Center &Institution; across India.” Mr. Raj Gore, CEO of HealthCare Global Enterprises Ltd. added, “I am extremely happy to share that we have once again outgrown the industry growth, and our revenues for Q3FY23 grew by 19% on a YoY basis to Rs 4,247 million. With accelerated awareness in the society for Cancer care &diagnosis; and HCG, being a trusted brand in the medical fraternity for Cancercare, we expect the revenue growth to improve and margins to enhance due to operating leverage play. We have seen growth in our volumes & patient count across modalities and with increased awareness, investments in digital technology, marketing initiatives & positive outcomes, we are optimistic of sustaining the growth momentum. At HCG, we believe in patient-centric care, focusing on accessible oncological services, advanced treatments, and high-quality care & outcomes. Over the years we have emerged as a responsible brand earning the trust of thousands of patients and the admiration of the community which has led us to be the leader in most of the markets, we are present in. Going forward, we continue to invest in HCG brand and penetrate deeper into the markets of our core geography and attain leadership position in newer territories through superior treatment & outcomes.” Result PDF10-02-2023
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Further to our intimation dated January 25, 2023, this is to inform the Stock Exchange(s) that the Audio recording of the Earnings Call held on February 09, 2023, with Analysts/Investors to discuss the Unaudited Financial Results of the quarter and nine months ended December 31, 2022, is made available on the website of the Company www.hcgoncology.com.09-02-2023
HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of schedule of investor meeting09-02-2023